While traditional cancer therapies like chemotherapy and radiation currently account for the most common forms of medical care today, newer immunological and biotherapy treatments will soon take up a larger share of the market, reaching 46% or $42 billion in sales by 2011.
There have been several successful new treatments products launched in the past, including Rituxan, Herceptin, Gleevec and Avastin. Their success has set the stage for belief that newer products will thrive just as well from a business standpoint. There are nearly 80 cancer immunotherapy products in late stage development for various cancer treatments, and therapeutics like Gardisil and Dacogen which have been recently approved, are likely to contribute to a further upsurge in the market.
The immunotherapy/
Newer therapies are gaining widespread acceptance across the world. They are particularly used to treat lymphoma and breast cancer, and have generated the most revenues from treatment in these two segments. Cervical, lung and multiple myelomas have only lately been benefiting from recent immunological therapies, and are expected to be at the forefront of treatment from immunological and biotherapies.
The study examines the global market for monoclonal antibodies, vaccines, interleukins and interferons, antisense oligonucleotides, and apoptosis or programmed cell death as well as other therapies used as cancer treatments.
The report also delineates the market shares for companies in the field, profiles key companies and their current products, has global data from across the world and forecasts to 2011 for sales of monoclonal antibodies,vaccines and other biotherapeutic treatments.
“Monoclonal Antibodies, Vaccines and Other Immunologic Cancer Treatments,”
Report Buyer product ID: KAL00018
